Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | MAPT | P10636 | 4/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7097377 | 0.66 | TDP1 (0.39) | SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL7667658 | 0.66 | ALDH1A1 (0.48) | SMN1; SMN2ALDH1A1MAPTLMNAGAA | |
| SCHEMBL7098074 | 0.65 | ESRRA (0.34) | ALDH1A1MAPTLMNAGAAMEN1 | |
| SCHEMBL7103291 | 0.65 | TDP1 (0.38) | SMN1; SMN2ALDH1A1MAPTLMNAMEN1 | |
| SCHEMBL7103262 | 0.64 | SMN1; SMN2 (0.34) | SMN1; SMN2ALDH1A1MAPTLMNAGAA | |
| SCHEMBL7100881 | 0.63 | ALDH1A1 (0.41) | ALDH1A1MAPTGAAMEN1KMT2A | |
| SCHEMBL7101733 | 0.62 | ALDH1A1 (0.31) | ALDH1A1MAPT | |
| SCHEMBL27818934 | 0.62 | MAPT (0.40) | SMN1; SMN2ALDH1A1MAPTLMNAGAA | |
| SCHEMBL7100452 | 0.61 | KMT2A (0.44) | SMN1; SMN2ALDH1A1MAPTLMNAGAA | |
| SCHEMBL7101641 | 0.60 | MEN1 (0.39) | SMN1; SMN2ALDH1A1MAPTGAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073850-A1 | 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use | ABBOTT LABORATORIES | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073850-A1 | 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use | ADRA1D, ADRB1, ADRA1A | SMN1; SMN2 639/4885ALDH1A1 263/4885MAPT 4075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.